Vivitrol

Phase 2Small molecule

NNew York State Psychiatric Institute

Vivitrol is one of 107 small molecule programs targeting Heroin Dependence. It is currently in Phase 2.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heroin DependenceActive, not recruiting

Opioid DependenceActive, not recruiting

Alcohol DependenceActive, not recruiting

Opioid Use DisorderActive, not recruiting

Heroin DependencePhase 2/Phase 3

Active, not recruiting

Opioid DependencePhase 2

Active, not recruiting

Alcohol DependencePhase 2

Active, not recruiting

Opioid Use DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Revia

Teva

Phase 3

2 2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

4 3

Epidiolex

Jazz Pharmaceuticals

Phase 2

5 4

Dayvigo

Eisai

Phase 2

2 5

Mounjaro

Eli Lilly

Phase 2

1 6

Ozempic

Novo Nordisk

Phase 2

1 7

Vraylar

AbbVie

Phase 2

1 8

Victoza

Novo Nordisk

Phase 2

1 9

Diamox

Teva

Phase 2

—10

Buprenorphine/naloxone

Astellas

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Opioid Dependence2 trials

The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence

Completed·JJohns Hopkins University·Phase 2·NCT01556425·84 enrolled

ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence

Completed·AAlkermes, Inc.·Phase 3·NCT00678418·250 enrolled

Buprenorphine2 trials

Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol

Terminated·NNew York State Psychiatric Institute·Phase 2/3·NCT03113409·10 enrolled

A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders

Completed·NNew York State Psychiatric Institute·Phase 3·NCT03232346·11 enrolled

MPA1 trial

Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

Completed·BBioCorRx Inc·Phase 1·NCT04828694·24 enrolled

Opioid Use Disorder1 trial

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Terminated·UUniversity of Pennsylvania·Phase 2·NCT04454411·3 enrolled

Oral1 trial

Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia

Completed·YYale University·Phase 3·NCT01389167·320 enrolled

10 more indications

Addiction1 trial

CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery

Completed·UUniversity of Pennsylvania·Phase 2·NCT01587196·72 enrolled

Opioid1 trial

Improved Strategies for Outpatient Opioid Detoxification

Completed·NNew York State Psychiatric Institute·Phase 1·NCT01377610·150 enrolled

Heroin Dependence1 trial

Memantine as a Supplement to Naltrexone in Treating Heroin Dependence

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00476242·82 enrolled

Efficacy and Safety1 trial

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

Completed·AAlkermes, Inc.·Phase 3·NCT00501631·300 enrolled

Alcohol Dependence1 trial

VIVITROL as a Treatment for Cocaine and Alcohol Dependence

Completed·UUniversity of Pennsylvania·Phase 2·NCT00777062·80 enrolled

Treatment1 trial

ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

Completed·AAlkermes, Inc.·Phase 4·NCT00511836·31 enrolled

Alcohol Use Disorder1 trial

Emergency Department Initiated Extended-Release Naltrexone and Case Management for the Treatment of Alcohol Use Disorder

Terminated·UUniversity of California, San Francisco·Phase 4·NCT04094584·179 enrolled

Clinical Trial1 trial

A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

Recruiting·IInventage Lab., Inc.·Phase 1·NCT05620940·40 enrolled

Prevention1 trial

A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration

Completed·AAlkermes, Inc.·Phase 4·NCT01453374·27 enrolled

Driving1 trial

Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders

Completed·PPacific Institute for Research and Evaluation·Phase 4·NCT00537745·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Vivitrol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vivitrol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vivitrol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York State Psychiatric Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNew York State Psychiatric Institute

Vivitrol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Opioid Dependence2 trials

Buprenorphine2 trials

MPA1 trial

Opioid Use Disorder1 trial

Oral1 trial

Addiction1 trial

Opioid1 trial

Heroin Dependence1 trial

Efficacy and Safety1 trial

Alcohol Dependence1 trial

Treatment1 trial

Alcohol Use Disorder1 trial

Clinical Trial1 trial

Prevention1 trial

Driving1 trial

References

Drug Info

Quick Facts

Related News